Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

About Clostridium Difficile Infection

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (BI /NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awarene
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... --  GenoSpace , a precision medicine software company that ... the broad use of genomic data in research and ... Phase I of a Fast Track Small Business Innovation ... (NIH) to enable enhanced data access and cohort construction ... During the past decade, the cost ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 Dr. ... my third book on healthcare offers a three phase ... 21st century healthcare delivery system that would go far ... state’s responsibility regarding the delivery of healthcare.” , “Every ... safety has failed to provide discernable progress throughout that ...
(Date:9/22/2014)... treated with a statin in the hospital after suffering ... survive than those who were not, according to a ... study was conducted by the same researchers who recently ... survival in victims of ischemic stroke., Ischemic stroke is ... vessel that blocks blood from reaching areas of the ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... men of action. Lies do not become us." , ,- ... business owners sometime seem like a big challenge to marketers. ... the right opportunity, however, small business owners can also be ... a desirable and growing market to many businesses. According to ...
... exodus continues at Merge Technologies, Inc. , ,The ... Healthcare, has announced that it received "a written notification from ... and president of Merge subsidiary Cedara Software , of ... 18. , ,Pedlar is the fifth executive to leave the ...
... - GE Healthcare will have the exclusive ... the terms of a 15-year agreement with its developer, ... will supply the stem cell harvesting product, known as the ... one of the world's largest chains of private umbilical cord ...
Cached Biology Technology:Big opportunities with small businesses 2Big opportunities with small businesses 3Pedlar the latest executive to leave Merge 2
(Date:9/23/2014)... today that the Company has secured $21 million in ... used to expand the Company,s cancer immunotherapy pipeline and ... Yuan Capital led the round, with participation from Majuven ... Suma Venture and Harbinger Venture Capital. , Eureka ... antibodies engineered to mimic the functions of a T ...
(Date:9/23/2014)... turn it is to do the washing up, negotiating rights ... as many students returning to university for the new academic ... house can be a tricky business. , And now research ... new technology to allow people to monitor their energy usage ... tension. , The study by a team of technology experts ...
(Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
Breaking Biology News(10 mins):Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3Eating five a day may keep the blues away 2
... specialized sensory organ that the malaria mosquito uses to ... of researchers has taken an important step toward developing ... used to reduce the threat of malaria, generally considered ... sensory organ is the maxillary palp. It is one ...
... at St. Jude Childrens Research Hospital provide strong evidence ... which has revolutionized the treatment of chronic myelogenous leukemia, ... particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted ... a specific molecule, a strategy aimed at making treatments ...
... may be attracted to more than the bananas that are ... carbonated water. Fruit flies detect and are attracted to the ... found on rotting fruits containing yeast, concludes a study appearing ... at the University of California, Berkeley, who conducted the study, ...
Cached Biology News:Advance in effort to fight malaria by tricking the mosquito's sense of smell 2Advance in effort to fight malaria by tricking the mosquito's sense of smell 3St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia 2Researchers find new taste in fruit flies: carbonated water 2Researchers find new taste in fruit flies: carbonated water 3
...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
Biology Products: